Pivotal's scientific team is composed of respected researchers with numerous other drugs in clinical trials throughout the world. Our business team includes experienced professionals who have managed drug development through clinical trials to FDA approval. The Advisory Board consist of distinguished scientists and scientist/businessmen who are actively assisting Pivotal Biosciences.

Business Team

CEO, ARTISTdirect, Inc; former Director of investment banking firm SG Cowen, active in venture capital as a member of the Tech Coast Angels.

President of Abraxis Pharmaceutrical Products, former COO of Tercica and Ligan Pharmaceuticals, 27 years at Hoffman-LaRoche.

20 year executive veteran in biotech R&D, with successful commercialization experience of biopharmaceuticals at PhotoThera, Egea BioSciences, Immune Response and other biotechnology companies.

Stephen Flaim, Ph.D.

Tech Coast Angels, Board of Governors; former Sr. VP, Gallileo Labs, Rega BioSciences; VP, Alliance Pharmaceuticals; Division Director, Bristol-Meyers Squibb

Science Team

Developed a novel method to target necrotic cells in human cancers, published over 120 articles on cancer research. Dr. Epstein currently has two cancer drugs in U.S. clinical trials with Peregrine Pharmaceuticals, Inc.

Pivotal's Scientific and Business Advisory Board consists of highly respected individuals in their scientific fields who provide an invaluable resource to Pivotal through the R&D process. Their collective experience includes domain expertise in the development and testing of new therapies for cancer, immunotherapy and vaccine development, infectious diseases, pharmacology, biophysics and structural biology at the USC Keck School of Medicine, M.D. Anderson Cancer Center/University of Texas, and The Mayo Clinic.

Scientific and Business Advisory Board

Robert Figlin, M.D., Chairman
Chair, Division of Medical Oncology & Therapeutics Research, City of Hope

Dr. Figlin is a former Professor at UCLA and a co-founder of Agensys.

Peter Anderson, M.D., Ph.D.
Associate Professor of Hematology/Oncology, Mayo Medical School

An expert on the development and testing of new therapies for cancer, especially in new formulations of IL-2 and methods to improve its half-life and delivery into patients.

A noted investigator of T-cell immunity who has devoted a large part of her career to the study and use of IL-2 for the treatment of cancer.

An experienced biotechnology executive who has both taken drugs through pre-clinical and clinical trials and has been involved with the financing of several biotech ventures.